TABLE 2
FROM:
Strategic alliances and competitive performance in the pharmaceutical industry
Francisco Rocha Gonçalves and Vítor da Conceição Gonçalves
BACK TO ARTICLETable 2. Results of the structural model estimation
| Hypothesis | Predicted effect | Estimated path | t-statistic | p-value < | Supports research hypothesis? | |||
|---|---|---|---|---|---|---|---|---|
| H1 | ALI |
| MSH | + | 0.50 | 3.26 | 0.01 | Yes |
| H1 | ALI |
| GRW | + | 0.54 | 4.06 | 0.01 | Yes |
| H1 | ALI |
| PRF | + | 0.14 | 0.39 | n/a | No |
| H2 | RCI |
| MSH | + | 0.24 | 1.81 | 0.05 | Yes |
| H2 | RCG |
| GRW | + | 0.34 | 2.57 | 0.01 | Yes |
| H2 | RCG |
| PRF | + | 0.59 | 1.86 | 0.05 | Yes |
| H3 | ALI |
| RCI | + | 0.63 | 7.34 | 0.01 | Yes |
| H3 | ALI |
| RCG | + | -0.20 | 0.78 | n/a | No |
| H4 | MSH |
| PRF | + | 0.33 | 2.48 | 0.01 | Yes |
| H4 | GRW |
| PRF | + | 0.30 | 0.98 | n/a | No |
| H5 | MOD |
| MSH | + | 0.21 | 2.30 | 0.03 | Yes |
| H5 | MOD |
| GRW | + | 0.27 | 3.16 | 0.01 | Yes |
n/a: p-value superior to commonly accepted values.